EVOLVING CLOSED LOOP MARKETING FOR PHARMA: THERE’S MORE THAN ONE LOOP TO CLOSE

whitePaper | November 11, 2022

Tremendous technological advancements in automated biotechnology and combinatorial chemistry have led to the widespread implementation of high throughput screening (HTS) for drug discovery since the early 1990s.

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

whitePaper | December 15, 2022

Successful execution of clinical trials requires the orchestration of multiple moving parts, with everything from protocol design and patient visit schedules, to lab kits and biological samples needing to seamlessly line up to ensure on-time, on-budget delivery of high-quality data.

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.